Risk-Sharing Agreement Services
In recent years, pharmaceutical companies have increasingly negotiated risk-sharing agreements for new drugs as part of the pricing and reimbursement process. These agreements seek to weigh the overall payment of the drug against its actual performance in the real world, reducing overall cost uncertainty for the payor.
IHS Global Insight provides specialized expertise in the area of risk-sharing agreements, offering three services that are specifically tailored to pricing and reimbursement (P&R) specialists who are considering their launch strategy for a new drug.
- Risk-Sharing Database: A continually updated online service that compares and contrasts agreements across all therapeutic areas, drugs, and geographies.
- Risk-Sharing Agreements: An Alternative Approach to Pricing Negotiations: A multi-client study delivering unique, in-depth analysis based on primary research (interviews with payors and key opinion leaders), providing cross-country comparison of the regulatory environment and market trends for risk-sharing agreements
- Risk-Sharing Quarterly Analysis: A quarterly bespoke PowerPoint deliverable that monitors new agreements and developments, as well as looks at key themes such as transparency, growth of risk sharing in emerging markets, and agreements that fail to secure reimbursement
|
|
|
